


CLAIMS


1. A compound having Formula I



Formula I


wherein G is H or a substituent, and wherein R¹ is any one of a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide group.

2. A compound according to claim 1 having Formula II



Formula II


3. A compound according to claim 1 having Formula III



Formula III

4. A compound according to claim 1 having Formula IV


151



Formula IV


5. A compound according to claim 1 having Formula VII

5.



Formula VII


6. A compound according to claim 1 having Formula VIII



Formula VIII


7. A compound according to claim 1 having Formula XI

15



Formula XI

8. A compound according to claim 1 having Formula XII



Formula XII

9. A compound according to claim 1 wherein G is H, OH or a hydrocarbyl group.
10. A compound according to claim 1 wherein G or the hydrocarbyl group is an optionally substituted hydrocarbon group.
11. A compound according to claim 1 wherein G or the hydrocarbyl group is an optionally substituted alkyl group.
12. A compound according to claim 1 wherein G or the hydrocarbyl group is selected from C₁-C₁₀ alkyl group, such as C₁-C₆ alkyl group, and C₁-C₃ alkyl group.
13. A compound according to claim 1 wherein G or the hydrocarbyl group is selected from C₁-C₁₀ haloalkyl group, C₁-C₆ haloalkyl group, C₁-C₃ haloalkyl group, C₁-C₁₀ bromoalkyl group, C₁-C₆ bromoalkyl group, and C₁-C₃ bromoalkyl group.
14. A compound according to claim 1 wherein G or the hydrocarbyl group is selected from -(CH₂)₁₋₁₀ aryl, -(CH₂)₁₋₁₀-Ph, (CH₂)₁₋₁₀-Ph-C₁₋₁₀ alkyl, -(CH₂)₁₋₅-Ph, (CH₂)₁₋₅-Ph-C₁₋₅ alkyl, -(CH₂)₁₋₃-Ph, (CH₂)₁₋₃-Ph-C₁₋₃ alkyl, -CH₂-Ph, and -CH₂-Ph-C(CH₃)₃.
15. A compound according to claim 1 wherein G or the hydrocarbyl group is selected from -(CH₂)₁₋₁₀ cycloalkyl, -(CH₂)₁₋₁₀-C₃₋₁₀cycloalkyl, -(CH₂)₁₋₇-C₃₋₇cycloalkyl, -(CH₂)₁₋₅-C₃₋₅cycloalkyl, -(CH₂)₁₋₃-C₃₋₅cycloalkyl, and -CH₂-C₃cycloalkyl.


16. A compound according to claim 1 wherein G or the hydrocarbonyl group is an alkene group.

17. A compound according to claim 1 wherein G or the hydrocarbonyl group is selected from C₁-C₁₀ alkene group, C₁-C₆ alkene group, C₁-C₃ alkene group.

5 18. A compound according to claim 1 wherein G is H.

19. A compound according to claim 1 wherein R¹ is a sulphamate group.

20. A compound according to claim 1 wherein R¹ or the sulphamate group is of the formula




10

wherein R⁴ and R⁵ are independently selected from H, alkyl, cycloalkyl, alkenyl and aryl, or combinations thereof, or together represent alkylene, wherein the or each alkyl or cycloalkyl or alkenyl or optionally contain one or more hetero atoms or groups.

15 21. A compound according to claim 20 wherein at least one of R⁴ and R⁵ is H.

22. A compound according to claim 21 wherein R⁴ and R⁵ are H.


23. A compound according to claim 1 having Formula XII



Formula XII

20 24. wherein G is selected from H, OH, C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, -(CH₂)₁₋₁₀-aryl, -(CH₂)₁₋₁₀-cycloalkyl, and C₁-C₁₀ alkene;

wherein R¹ is OH or a sulphamate group of the formula



- wherein R⁴ and R⁵ are independently selected from H, alkyl, cycloalkyl, alkenyl and aryl, or combinations thereof, or together represent alkylene, wherein the or each alkyl or cycloalkyl or alkenyl or optionally contain one or more hetero atoms or groups.
24. A pharmaceutical composition comprising a compound according to claim 1 optionally admixed with a pharmaceutically acceptable carrier, diluent, excipient or adjuvant.
 25. A compound according to claim 1 for use in medicine.
 26. A method of using a compound according to claim 1 in the manufacture of a medicament for use in the therapy of a condition or disease associated with steroid sulphatase (STS).
 27. A method of using a compound according to claim 1 in the manufacture of a medicament for use in the therapy of a condition or disease associated with adverse STS levels.
 28. A method of using a compound according to claim 1 in the manufacture of a pharmaceutical for inhibiting steroid sulphatase (STS) activity.
 29. A method of using a compound according to claim 1 in the manufacture of a pharmaceutical for inhibiting steroid sulphatase (STS) activity.
 30. A method comprising (a) performing a steroid sulphatase assay with one or more candidate compounds having the formula as defined in claim 1; (b) determining whether one or more of said candidate compounds is/are capable of modulating STS activity; and (c) selecting one or more of said candidate compounds that is/are capable of modulating STS activity.
 31. A method comprising (a) performing a steroid sulphatase assay with one or more candidate compounds having the formula as defined in claim 1; (b) determining whether one or more of said candidate compounds is/are capable of inhibiting STS activity; and (c) selecting one or more of said candidate compounds that is/are capable of inhibiting STS activity.
 32. A compound identified by the method according to claim 30.
 33. A compound identified by the method according to claim 31.
 34. A compound according to claim 32 for use in medicine.
 35. A compound according to claim 33 for use in medicine.
 36. A pharmaceutical composition comprising the compound according to claim 32 optionally admixed with a pharmaceutically acceptable carrier, diluent, excipient or adjuvant.

37. A pharmaceutical composition comprising the compound according to claim 33 optionally admixed with a pharmaceutically acceptable carrier, diluent, excipient or adjuvant.

5 38. A method of using a compound according to claim 32 in the manufacture of a medicament for use in the therapy of a condition or disease associated with STS.

39. A method of using a compound according to claim 33 in the manufacture of a medicament for use in the therapy of a condition or disease associated with STS.

10 40. A method of using a compound according to claim 32 in the manufacture of a medicament for use in the therapy of a condition or disease associated with adverse STS levels.

41. A method of using a compound according to claim 33 in the manufacture of a medicament for use in the therapy of a condition or disease associated with adverse STS levels.